Eficacia y seguridad de las vacunas contra el dengue
Dengue virus infection is considered a public health issue due to the morbidity and mortality it causes, particularly in endemic countries. To address this, vaccines have been developed to reduce the global impact. Objective: To consolidate the available evidence on the efficacy and safety of dengue...
Saved in:
| Main Author: | |
|---|---|
| Format: | masterThesis |
| Language: | spa |
| Published: |
2025
|
| Subjects: | |
| Online Access: | https://dspace.uniandes.edu.ec/handle/123456789/19552 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Add Tag | Summary: | Dengue virus infection is considered a public health issue due to the morbidity and mortality it causes, particularly in endemic countries. To address this, vaccines have been developed to reduce the global impact. Objective: To consolidate the available evidence on the efficacy and safety of dengue vaccines (CYD-TDV, TAK-003, and TV003/TV005). Methodology: A systematic review of articles published on PubMed and Scopus was conducted using keywords and Boolean operators. Studies published between 2014 and 2024, no older than 10 years, were included. These studies evaluated the immune response, efficacy, and safety of the vaccines in different populations and age groups. Results: Applying search criteria, 35 publications were identified. Few dengue vaccines have completed Phase III clinical trials. CYD-TDV was the first vaccine approved, followed by TAK-003; both are highly effective in seropositive individuals, although CYD-TDV poses risks for seronegative individuals. TV003/TV005, the third approved vaccine, offers balanced protection but remains under investigation. TAK-003 is more effective in children aged 4–16, while TV003/TV005 is effective across all age groups. Conclusions: Age and serological status play a crucial role in vaccine response. TV003/TV005 appears to be more effective than the vaccines currently in circulation, but further research is needed, especially on the duration of immunity and efficacy against DENV-3 and DENV-4. |
|---|